Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA3 | P22001 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | NQO2 | P16083 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | BRD4 | O60885 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30783436 | 0.81 | KCNA3 (0.61) | KCNA3KDM4ENQO2HSD17B10SMN1; SMN2 | |
| SCHEMBL11379787 | 0.81 | KCNA3 (0.61) | KCNA3KDM4ENQO2HSD17B10SMN1; SMN2 | |
| SCHEMBL11375444 | 0.77 | KCNA3 (0.69) | KCNA3KDM4ENQO2HSD17B10SMN1; SMN2 | |
| SCHEMBL29206051 | 0.76 | KCNA3 (0.56) | KCNA3KDM4ENQO2HSD17B10SMN1; SMN2 | |
| SCHEMBL1685941 | 0.76 | KCNA3 (0.37) | KCNA3KDM4ENQO2HSD17B10SMN1; SMN2 | |
| SCHEMBL11389662 | 0.75 | KCNA3 (0.74) | KCNA3SMN1; SMN2ALDH1A1HPGDBRD4 | |
| SCHEMBL3971661 | 0.75 | ALDH1A1 (0.56) | ALDH1A1LMNARAB9A | |
| SCHEMBL30807999 | 0.75 | KDM4E (0.66) | KCNA3KDM4ENQO2HSD17B10ALDH1A1 | |
| SCHEMBL18026627 | 0.74 | KCNA3 (0.64) | KCNA3KDM4ENQO2HSD17B10SMN1; SMN2 | |
| SCHEMBL11385254 | 0.74 | KCNA3 (0.77) | KCNA3SMN1; SMN2ALDH1A1HPGDBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120009226-A1 | HIGHLY PURE LAQUINIMOD OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ACTAVIS GROUP PTC EHF (IS) | 2012-01-12 | — | — | US | claimed |
| US-20120009226-A1 | HIGHLY PURE LAQUINIMOD OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ACTAVIS GROUP PTC EHF (IS) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120009226-A1 | HIGHLY PURE LAQUINIMOD OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TLR7, MYD88, PDE7A | KCNA3 4582/4885KDM4E 422/4885NQO2 413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.